Early Effect of Fasting on Metabolic, Inflammatory, and Behavioral Responses in Females With and Without Obesity

Not Applicable

Completed

• Conditions: Healthy; Obese
• Interventions: Other: Acute Fasting

• Registration Number: NCT03532672
• Lead Sponsor: Federal University of Minas Gerais

Brief Summary

The aim of this study is to investigate the effect of overnight fasting versus a diurnal fasting (during daily life activities) in females with and without obesity on inflammation, neurotrophins, energy metabolism, mood, food cravings, and appetite sensations.

This study will be an acute fasting intervention.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-09-22
• Study First Submitted: 2018-05-07
• Study First Submitted QC: 2018-05-19
• Study First Posted: 2018-05-22
• Primary Completion: 2019-03-26
• Study Completion: 2022-12-31
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-18
• Last Update Posted: 2025-03-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 54

Inclusion Criteria

• Body mass index between 18.5 and 24.9 kg/m² or equal or greater 35 kg/m²;
• Able to sign the informed consent.

Exclusion Criteria

• Chronic health conditions (e.g., cancer, renal, heart or liver disorders, and autoimmune diseases), or history of thyroid alterations or use of related medications;
• Use of corticosteroids, immunosuppressors, anti-inflammatories, hypoglycemics, medications for weight loss, or any medication known to interfere with metabolic and inflammatory processes (e.g., corticosteroids, nonsteroidal anti-inflammatory drugs);
• Previous surgery for weight loss;
• Inability to eat any of the components of the standardized breakfast
• Pregnancy or breastfeeding;
• Smokingç
• Alcohol use (>2 doses/day).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Acute fasting	Acute Fasting	Participants will fast overnight for 10 hours (resting period), consume a santdardized breakfast, and fast during daily activities (active period) for another 10 hours.

Primary Outcome Measures

Name	Time	Method
Blood glucose	At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours)	Changes in blood glucose will be assessed at baseline and after 10 hours of fasting during daily activities
Lipid panel	At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours)	Changes in lipid panel (i.e. total cholesterol, LDL, HDL and triglycerides) will be assessed at baseline and after 10 hours of fasting during daily activities
Interleukin 6	At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours)	Changes in blood interleukin-6 will be assessed at baseline and after 10 hours of fasting during daily activities
Appetite sensations	At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours)	Changes in hunger, satiety, fullness, and prospective food consumption will be assessed at baseline and after 10 hours of fasting during daily activities using a 100 mm visual analogue scale
Mood states	At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours)	Changes in anger, confusion, depression, fatigue, tension, and vigor will be assessed using the Brunel Mood Scale

Secondary Outcome Measures

Name	Time	Method
Gastrointestinal peptides	At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours)	Changes in resting energy expenditure will be assessed at baseline and after 10 hours of fasting during daily activities using indirect calorimetry
Free fatty acids	At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours)	Changes in free fatty acids will be assessed at baseline and after 10 hours of fasting during daily activities
Neurotrophic factors	At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours)	Changes in brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and nerve growth factor (NGF) will be assessed at baseline and after 10 hours of fasting during daily activities

Trial Locations

Locations (1)

Hospital das Clínicas da Universidade Federal de Minas Gerais; 🇧🇷 Belo Horizonte, Minas Gerais, Brazil